390 related articles for article (PubMed ID: 28760313)
1. Recent advances (2015-2016) in anticancer hybrids.
Kerru N; Singh P; Koorbanally N; Raj R; Kumar V
Eur J Med Chem; 2017 Dec; 142():179-212. PubMed ID: 28760313
[TBL] [Abstract][Full Text] [Related]
2. Advances in the development of hybrid anticancer drugs.
Fortin S; Bérubé G
Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
[TBL] [Abstract][Full Text] [Related]
3. Coumarin-containing hybrids and their anticancer activities.
Zhang L; Xu Z
Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864
[TBL] [Abstract][Full Text] [Related]
4. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids.
Nepali K; Sharma S; Sharma M; Bedi PM; Dhar KL
Eur J Med Chem; 2014 Apr; 77():422-87. PubMed ID: 24685980
[TBL] [Abstract][Full Text] [Related]
5. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Xu Z; Zhao SJ; Liu Y
Eur J Med Chem; 2019 Dec; 183():111700. PubMed ID: 31546197
[TBL] [Abstract][Full Text] [Related]
6. Recent Development of Sulfonyl or Sulfonamide Hybrids as Potential Anticancer Agents: A Key Review.
Rakesh KP; Wang SM; Leng J; Ravindar L; Asiri AM; Marwani HM; Qin HL
Anticancer Agents Med Chem; 2018; 18(4):488-505. PubMed ID: 29110622
[TBL] [Abstract][Full Text] [Related]
7. Hydroxamic acid hybrids as the potential anticancer agents: An Overview.
Liu W; Liang Y; Si X
Eur J Med Chem; 2020 Nov; 205():112679. PubMed ID: 32791404
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in isatin hybrids as potential anticancer agents.
Ding Z; Zhou M; Zeng C
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
[TBL] [Abstract][Full Text] [Related]
9. An overview of molecular hybrids in drug discovery.
Bérubé G
Expert Opin Drug Discov; 2016; 11(3):281-305. PubMed ID: 26727036
[TBL] [Abstract][Full Text] [Related]
10. Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs.
Zhang X; Rakesh KP; Shantharam CS; Manukumar HM; Asiri AM; Marwani HM; Qin HL
Bioorg Med Chem; 2018 Jan; 26(2):340-355. PubMed ID: 29269253
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Compounds as Multitarget Directed Anticancer Agents.
Kucuksayan E; Ozben T
Curr Top Med Chem; 2017; 17(8):907-918. PubMed ID: 27697050
[TBL] [Abstract][Full Text] [Related]
12. Artemisinin-derived hybrids and their anticancer activity.
Gao F; Sun Z; Kong F; Xiao J
Eur J Med Chem; 2020 Feb; 188():112044. PubMed ID: 31945642
[TBL] [Abstract][Full Text] [Related]
13. Isatin-azole hybrids and their anticancer activities.
Hou Y; Shang C; Wang H; Yun J
Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
[TBL] [Abstract][Full Text] [Related]
14. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
15. 1,2,3-Triazole hybrids as anticancer agents: A review.
Alam MM
Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100158. PubMed ID: 34559414
[TBL] [Abstract][Full Text] [Related]
16. Tetrazole hybrids with potential anticancer activity.
Zhang J; Wang S; Ba Y; Xu Z
Eur J Med Chem; 2019 Sep; 178():341-351. PubMed ID: 31200236
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure-activity relationship, and mechanisms of action (2019-2021).
Feng LS; Su WQ; Cheng JB; Xiao T; Li HZ; Chen DA; Zhang ZL
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200051. PubMed ID: 35385159
[TBL] [Abstract][Full Text] [Related]
18. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
19. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.
Dong G; Jiang Y; Zhang F; Zhu F; Liu J; Xu Z
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200479. PubMed ID: 36372519
[TBL] [Abstract][Full Text] [Related]
20. Anticancer hybrids--a patent survey.
Nepali K; Sharma S; Kumar D; Budhiraja A; Dhar KL
Recent Pat Anticancer Drug Discov; 2014; 9(3):303-39. PubMed ID: 24846460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
